Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma
The proposed adaptation expands the range of available approaches for the estimation of the (local) ATE for survival outcomes in health technology assessments using "doubly robust" methods. This approach appeared relatively robust to modelling decisions in our case study.
Authors
- S.A. Mitchell (ORCID: https://orcid.org/0000-0003-3414-0581)
- Sarah Batson (ORCID: https://orcid.org/0009-0006-4062-5648)
- Danilo Di Maio (ORCID: https://orcid.org/0009-0007-3975-508X)
- Howard Thom (ORCID: https://orcid.org/0000-0001-8576-5552)
- Edna Keeney (ORCID: https://orcid.org/0000-0002-4763-8891)
Institutions
- Roche (Switzerland) (CH)
- University of Bristol (GB)
- Clifton Hospital (GB)
Publication Details
- Journal
- BMC Medical Research Methodology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1186/s12874-025-02456-x
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roche
- F. Hoffmann-La Roche